MX2016002571A - Regulador de ph de transduccion. - Google Patents

Regulador de ph de transduccion.

Info

Publication number
MX2016002571A
MX2016002571A MX2016002571A MX2016002571A MX2016002571A MX 2016002571 A MX2016002571 A MX 2016002571A MX 2016002571 A MX2016002571 A MX 2016002571A MX 2016002571 A MX2016002571 A MX 2016002571A MX 2016002571 A MX2016002571 A MX 2016002571A
Authority
MX
Mexico
Prior art keywords
buffers
methods
relates
transduction buffer
transduction
Prior art date
Application number
MX2016002571A
Other languages
English (en)
Inventor
Niels Geijsen
Diego Sebastián D Astolfo
Original Assignee
Koninklijke Nederlandse Akademie Van Wetenschappen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Koninklijke Nederlandse Akademie Van Wetenschappen filed Critical Koninklijke Nederlandse Akademie Van Wetenschappen
Publication of MX2016002571A publication Critical patent/MX2016002571A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/32—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bacillus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/07—Nucleotidyltransferases (2.7.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)

Abstract

La invención se refiere a compuestos de transducción, reguladores de pH y métodos para la introducción de moléculas en células. La invención también se refiere a métodos de tratamiento, composiciones farmacéuticas y otros usos de los compuestos de transducción y reguladores de pH. La invención también se refiere a células modificadas que pueden obtenerse por los compuestos de transducción, reguladores de pH y métodos de la invención.
MX2016002571A 2013-08-28 2014-08-28 Regulador de ph de transduccion. MX2016002571A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1315321.8A GB201315321D0 (en) 2013-08-28 2013-08-28 Transduction Buffer
PCT/IB2014/064127 WO2015028969A2 (en) 2013-08-28 2014-08-28 Transduction buffer

Publications (1)

Publication Number Publication Date
MX2016002571A true MX2016002571A (es) 2016-06-14

Family

ID=49356013

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016002571A MX2016002571A (es) 2013-08-28 2014-08-28 Regulador de ph de transduccion.

Country Status (18)

Country Link
US (2) US10883116B2 (es)
EP (2) EP4036240A3 (es)
JP (2) JP6917711B2 (es)
KR (1) KR102267151B1 (es)
CN (2) CN112980889A (es)
AU (1) AU2014313782B2 (es)
CA (1) CA2922391C (es)
DK (1) DK3039148T3 (es)
ES (1) ES2897625T3 (es)
GB (1) GB201315321D0 (es)
HK (1) HK1226094A1 (es)
HU (1) HUE057403T2 (es)
IL (1) IL244311B (es)
MX (1) MX2016002571A (es)
NZ (1) NZ717784A (es)
PT (1) PT3039148T (es)
SG (2) SG11201601433TA (es)
WO (1) WO2015028969A2 (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10323236B2 (en) 2011-07-22 2019-06-18 President And Fellows Of Harvard College Evaluation and improvement of nuclease cleavage specificity
US20150044192A1 (en) 2013-08-09 2015-02-12 President And Fellows Of Harvard College Methods for identifying a target site of a cas9 nuclease
US9359599B2 (en) 2013-08-22 2016-06-07 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
US9322037B2 (en) 2013-09-06 2016-04-26 President And Fellows Of Harvard College Cas9-FokI fusion proteins and uses thereof
US9228207B2 (en) 2013-09-06 2016-01-05 President And Fellows Of Harvard College Switchable gRNAs comprising aptamers
US9737604B2 (en) 2013-09-06 2017-08-22 President And Fellows Of Harvard College Use of cationic lipids to deliver CAS9
US20150166984A1 (en) 2013-12-12 2015-06-18 President And Fellows Of Harvard College Methods for correcting alpha-antitrypsin point mutations
EP3177718B1 (en) 2014-07-30 2022-03-16 President and Fellows of Harvard College Cas9 proteins including ligand-dependent inteins
CN104962523B (zh) * 2015-08-07 2018-05-25 苏州大学 一种测定非同源末端连接修复活性的方法
WO2017070632A2 (en) 2015-10-23 2017-04-27 President And Fellows Of Harvard College Nucleobase editors and uses thereof
WO2017087861A1 (en) * 2015-11-19 2017-05-26 Novartis Ag Buffers for stabilzation of lentiviral preparations
GB201521101D0 (en) * 2015-11-30 2016-01-13 Koninklijke Nederlandse Akademie Van Wetenschappen Transduction buffer
WO2017189821A1 (en) * 2016-04-29 2017-11-02 Bio-Rad Laboratories, Inc. Dimeric proteins for specific targeting of nucleic acid sequences
KR20230095129A (ko) 2016-08-03 2023-06-28 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 아데노신 핵염기 편집제 및 그의 용도
US11661590B2 (en) 2016-08-09 2023-05-30 President And Fellows Of Harvard College Programmable CAS9-recombinase fusion proteins and uses thereof
WO2018039438A1 (en) 2016-08-24 2018-03-01 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
CN109790541B (zh) * 2016-09-29 2022-12-09 豪夫迈·罗氏有限公司 分析并优化基因编辑模块和递送方案的方法
US11306324B2 (en) 2016-10-14 2022-04-19 President And Fellows Of Harvard College AAV delivery of nucleobase editors
WO2018119359A1 (en) 2016-12-23 2018-06-28 President And Fellows Of Harvard College Editing of ccr5 receptor gene to protect against hiv infection
TW201839136A (zh) 2017-02-06 2018-11-01 瑞士商諾華公司 治療血色素異常症之組合物及方法
EP3592853A1 (en) 2017-03-09 2020-01-15 President and Fellows of Harvard College Suppression of pain by gene editing
KR20190127797A (ko) 2017-03-10 2019-11-13 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 시토신에서 구아닌으로의 염기 편집제
US11268082B2 (en) 2017-03-23 2022-03-08 President And Fellows Of Harvard College Nucleobase editors comprising nucleic acid programmable DNA binding proteins
CN106967686B (zh) * 2017-03-31 2019-11-08 北昊干细胞与再生医学研究院有限公司 软骨细胞体外端粒延长增殖培养的方法及人源组织工程化再生软骨
US11560566B2 (en) 2017-05-12 2023-01-24 President And Fellows Of Harvard College Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation
EP3658573A1 (en) 2017-07-28 2020-06-03 President and Fellows of Harvard College Methods and compositions for evolving base editors using phage-assisted continuous evolution (pace)
EP3676376A2 (en) 2017-08-30 2020-07-08 President and Fellows of Harvard College High efficiency base editors comprising gam
US11795443B2 (en) 2017-10-16 2023-10-24 The Broad Institute, Inc. Uses of adenosine base editors
CN107988267A (zh) * 2017-12-18 2018-05-04 赛业（苏州）生物科技有限公司 一种高通量对受精卵进行基因编辑的电转方法
CA3100323A1 (en) * 2018-05-14 2019-11-21 Roosterbio, Inc. Methods and compositions related to extracellular material derived from hypertonic cell solutions
CN108893539B (zh) * 2018-06-08 2021-11-19 中国农业科学院北京畜牧兽医研究所 猪肉质性状相关的circRNA及其应用
CN113195003A (zh) 2018-11-30 2021-07-30 国立大学法人京都大学 使用溶液的药物递送***
CN113891937A (zh) 2019-03-19 2022-01-04 布罗德研究所股份有限公司 编辑核苷酸序列的方法和组合物
GB201915346D0 (en) * 2019-06-21 2019-12-04 Lumiradx Tech Ltd Improvements in or relating to nicking enzymes
IL297761A (en) 2020-05-08 2022-12-01 Broad Inst Inc Methods and compositions for simultaneously editing two helices of a designated double-helix nucleotide sequence
EP4367254A1 (en) 2021-07-07 2024-05-15 Ntrans Technologies BV Transduction buffer
WO2023224112A1 (ja) * 2022-05-20 2023-11-23 株式会社ダイセル 液状医薬組成物

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5627159A (en) 1994-10-27 1997-05-06 Life Technologies, Inc. Enhancement of lipid cationic transfections in the presence of serum
FR2732895B1 (fr) 1995-04-11 1997-05-16 Pasteur Merieux Serums Vacc Utilisation d'un compose amphipathique cationique comme agent de transfection, comme adjuvant de vaccin, ou comme medicament
LV11728B (en) 1995-08-21 1997-08-20 Kalvins Ivars Pharmaceutical composition
US6258792B1 (en) * 1996-04-12 2001-07-10 University Of Pittsburgh Cationic cholesteryl derivatives containing cyclic polar groups
US6482804B1 (en) 1997-10-28 2002-11-19 Wyeth Compositions and methods for delivery of genetic material
IL139688A0 (en) * 1998-05-15 2002-02-10 Neurochem Inc Use of amyloid inhibitors for modulating neuronal cell death
US6124207A (en) 1998-08-31 2000-09-26 Micron Technology, Inc. Slurries for mechanical or chemical-mechanical planarization of microelectronic-device substrate assemblies, and methods and apparatuses for making and using such slurries
JP2000143486A (ja) 1998-11-12 2000-05-23 Lion Corp 皮膚外用剤
EP1046394A3 (en) 1999-04-19 2001-10-10 ImaRx Pharmaceutical Corp. Novel compositions useful for delivering compounds into a cell
DE19956772A1 (de) 1999-11-25 2001-06-07 Basf Ag Verwendung von y-Butyrobetain Salzen zur Herstellung von Zubereitungen für die menschliche und tierische Ernährung
WO2001072280A2 (en) 2000-03-24 2001-10-04 Biosphere Medical Inc. Microspheres for gene therapy
AU2001259760B2 (en) * 2000-05-12 2006-10-05 Northwest Biotherapeutics, Inc. Method to increase class I presentation of exogenous antigens by human dendritic cells
SI21639A (sl) * 2003-12-23 2005-06-30 LEK farmacevtska dru�ba d.d. Farmacevtski pripravek, ki vsebuje nemicelarne sulfobetaine
EP1833838A2 (en) * 2004-12-14 2007-09-19 Applera Corporation, Applied Biosystems Group Cationic liposomes comprising a charge neutral compound and a cationic phospholipid
US8143236B2 (en) * 2005-12-13 2012-03-27 Bionumerik Pharmaceuticals, Inc. Chemoprotective methods
CA2676797C (en) * 2007-01-29 2014-04-22 Dae Woong Jo Novel macromolecule transduction domains and methods for identification and uses thereof
US8680366B2 (en) 2007-06-07 2014-03-25 Agriculture And Agri-Food Canada Nanocarrier based plant transfection and transduction
WO2009141738A2 (en) 2008-05-23 2009-11-26 The University Of British Columbia Modified drugs for use in liposomal nanoparticles
US8381290B2 (en) * 2009-07-17 2013-02-19 Exelis Inc. Intrusion detection systems and methods
DE112011103442T5 (de) * 2010-10-12 2013-08-14 The Yokohama Rubber Co., Ltd. Elektrolyt für photoelektrisches Umwandlungselement sowie photoelektrisches Umwandlungselement und farbstoffsensibilisierte Solarzelle, die denselben verwenden
CZ201181A3 (cs) * 2011-02-15 2012-09-12 Ústav organické chemie a biochemie Akademie ved CR, v.v.i. Deriváty pregnanolonu substituované v poloze 3alfa kationickou skupinou, zpusob jejich výroby, jejich použití a prostredek je obsahující
CN103608041A (zh) * 2011-06-27 2014-02-26 英特维特国际股份有限公司 包含生物性抗原和丙烯酸聚合物的水性组合物
CA2858117A1 (en) * 2011-12-15 2013-06-20 Dow Agrosciences Llc Method for improved transformation using agrobacterium
EP2975942B1 (en) * 2013-03-21 2018-08-08 Sangamo Therapeutics, Inc. Targeted disruption of t cell receptor genes using engineered zinc finger protein nucleases
US9737604B2 (en) * 2013-09-06 2017-08-22 President And Fellows Of Harvard College Use of cationic lipids to deliver CAS9
WO2015069571A1 (en) * 2013-11-05 2015-05-14 Bavarian Nordic, Inc. Combination therapy for treating cancer with a poxvirus expressing a tumor antigen and an antagonist and/or agonist of an immune checkpoint inhibitor
GB201521101D0 (en) 2015-11-30 2016-01-13 Koninklijke Nederlandse Akademie Van Wetenschappen Transduction buffer

Also Published As

Publication number Publication date
HUE057403T2 (hu) 2022-05-28
CA2922391C (en) 2021-08-03
ES2897625T3 (es) 2022-03-02
JP7055168B2 (ja) 2022-04-15
CN112980889A (zh) 2021-06-18
US20210087585A1 (en) 2021-03-25
AU2014313782B2 (en) 2020-08-06
EP3039148A2 (en) 2016-07-06
IL244311B (en) 2021-10-31
US10883116B2 (en) 2021-01-05
JP2016535999A (ja) 2016-11-24
JP6917711B2 (ja) 2021-08-11
CA2922391A1 (en) 2015-03-05
EP3039148B1 (en) 2021-08-18
JP2020146056A (ja) 2020-09-17
KR102267151B1 (ko) 2021-06-22
NZ717784A (en) 2021-07-30
WO2015028969A3 (en) 2015-08-20
IL244311A0 (en) 2016-04-21
US20160273001A1 (en) 2016-09-22
KR20160056899A (ko) 2016-05-20
SG10201802627TA (en) 2018-04-27
WO2015028969A2 (en) 2015-03-05
CN105637093B (zh) 2021-04-06
HK1226094A1 (zh) 2017-09-22
CN105637093A (zh) 2016-06-01
SG11201601433TA (en) 2016-03-30
EP4036240A2 (en) 2022-08-03
GB201315321D0 (en) 2013-10-09
EP4036240A3 (en) 2022-10-12
DK3039148T3 (da) 2021-11-08
PT3039148T (pt) 2021-11-16
AU2014313782A1 (en) 2016-03-17

Similar Documents

Publication Publication Date Title
MX2016002571A (es) Regulador de ph de transduccion.
PH12018500707A1 (en) Anti-human cd19 antibodies with high affinity
PH12018500714A1 (en) Anti-tigit antigen-binding proteins and methods of use thereof
MX2015012401A (es) Composiciones y metodos de alterar niveles de colesterol.
AU2016204248A1 (en) Boron-Containing Molecules
PH12016501192B1 (en) Tetrahydropyridopyrazines modulators of gpr6
PH12014502010A1 (en) Bispecific antibodies against human tweak and human il17 and uses thereof
MX2015012502A (es) Inhibidores de proteina cinasa dependiente de adn.
PH12017500864A1 (en) Anti-notch1 antibodies
WO2015085318A3 (en) Targeted adaptive vaccines
NZ726859A (en) Synthesis of polycyclic-carbamoylpyridone compounds
JO3773B1 (ar) معدلات p2x7
MX2014009289A (es) Anticuerpos c1orf32 y usos de los mismos para el tratamiento del cancer.
EA201491412A1 (ru) Соединения для лечения спинальной мышечной атрофии
IN2014DN08481A (es)
PH12016501366A1 (en) Novel anti-baff antibodies
EA201590887A1 (ru) Композиция
EA201591712A1 (ru) Антибиотические композиции на основе цефтолозана
EA201600026A1 (ru) Бактериальная гиалуронидаза и способ ее производства
AU2018253594A1 (en) Dihydroxyphenyl neurotransmitter compounds, compositions and methods
TN2015000277A1 (en) Bmp-6 antibodies
MX2015000179A (es) Composiciones y formas de dosificacion de itraconazol y metodos de uso de las mismas.
MX2015016603A (es) Composiciones de corticosteroides.
IN2013MU01927A (es)
IN2013CH05591A (es)